KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis

Journal of Clinical Investigation

Volumn 118, Issue 8, 2008, Pages 2711-2721

  Narla, Goutham ^a   DiFeo, Analisa ^a   Fernandez, Yolanda ^a   Dhanasekaran, Saravana ^b   Huang, Fei ^a   Sangodkar, Jaya ^a   Hod, Eldad ^a   Leake, Devin ^c   Friedman, Scott L ^a   Hall, Simon J ^a   Chinnaiyan, Arul M ^b   Gerald, William L ^d   Rubin, Mark A ^e   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Thermo Fisher Scientific   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 6; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; BRAIN METASTASIS; CANCER INHIBITION; CANCER MODEL; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASTIC PROCESSES; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 48749088691     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34780     Document Type: Article

References (37)

1. Jemal, A., et al. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57:43-66.
2. Narla, G., et al. 2001. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 294:2563-2566.
3. Chen, C., et al. 2003. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am. J. Pathol. 162:1349-1354.
4. Reeves, H.L., et al. 2004. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 126:1090-1103.
5. Kremer-Tal, S., et al. 2004. Frequent inactivation of the tumor suppressor kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 40:1047-1052.
6. Chen, H.K., et al. 2002. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng. 21:1047-1050.
7. Jeng, Y.M., and Hsu, H.C. 2003. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int. J. Cancer. 105:625-629.
8. Yamashita, K., et al. 2002. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2:485-495.
9. Kettunen, E., et al. 2004. Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet. Cytogenet. 149:98-106.
10. Ito, G., et al. 2004. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 64:3838-3843.
11. Glinsky, G.V., Glinskii, A.B., Stephenson, A.J., Hoffman, R.M., and Gerald, W.L. 2004. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113:913-923.
12. Singh, D., et al. 2002. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:203-209.
13. Macleod, K., et al. 2005. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65:6789-6800.
14. Narla, G., et al. 2005. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65:1213-1222.
15. Narla, G., et al. 2005. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65:5761-5768.
16. Dhanasekaran, S.M., et al. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822-826.
17. Benzeno, S., et al. 2004. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 64:3885-3891.
18. Slavin, D.A., et al. 2004. A new role for the kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene. 23:8196-8205.
19. Kimmelman, A.C., et al. 2004. Suppression of glioblastoma tumorigenicity by the kruppel-like transcription factor KLF6. Oncogene. 23:5077-5083.
20. DiFeo, A., et al. 2006. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 25:6026-6031.
21. Lyons, S.K., et al. 2006. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res. 66:4701-4707.
22. Drake, J.M., Gabriel, C.L., and Henry, M.D. 2005. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin. Exp. Metastasis. 22:674-684.
23. Shih, S.C., et al. 2002. Molecular profiling of angiogenesis markers. Am. J. Pathol. 161:35-41.
24. Xie, F.Y., Woodle, M.C., and Lu, P.Y. 2006. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today. 11:67-73.
25. Fidler, I.J. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer. 3:453-458.
26. Steeg, P.S. 2006. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12:895-904.
27. Kang, Y., et al. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3:537-549.
28. Minn, A.J., et al. 2005. Genes that mediate breast cancer metastasis to lung. Nature. 436:518-524.
29. van 't Veer, L.J., et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-536.
30. van de Vijver, M.J., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009.
31. Ramaswamy, S., Ross, K.N., Lander, E.S., and Golub, T.R. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49-54.
32. Sooriakumaran, P., Khaksar, S.J., and Shah, J. 2006. Management of prostate cancer. Part 2: localized and locally advanced disease. Expert Rev. Anticancer Ther. 6:595-603.
33. Bhandari, M.S., Petrylak, D.P., and Hussain, M. 2005. Clinical trials in metastatic prostate cancer - has there been real progress in the past decade? Eur. J. Cancer. 41:941-953.
34. Stanbrough, M., et al. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66:2815-2825.
35. Rinker-Schaeffer, C.W., O'Keefe, J.P., Welch, D.R., and Theodorescu, D. 2006. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin. Cancer Res. 12:3882-3889.
36. Mehlen, P., and Puisieux, A. 2006. Metastasis: a question of life or death. Nat. Rev. Cancer. 6:449-458.
37. Stephenson, A.J., et al. 2005. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 104:290-298.